Obesity Is Associated With Residual Disease Activity and Lower Quality of Life in Patients Who Achieve Clinical Response to Psoriatic Arthritis Treatment: Post Hoc Analysis From the SPIRIT Studies

Main Article Content

Joseph F. Merola
UT Southwestern Medical Center, Dallas, Texas, USA

William Tillett
University of Bath, Bath, UK

Uta Kiltz
Rheumazentrum Ruhrgebiet, Herne, Germany; Ruhr University Bochum, Bochum, Germany

Elizabeth L. Perkins
Rheumatology Care Center, Hoover, Alabama, USA

Allyson Perry
Eli Lilly and Company, Indianapolis, Indiana, USA

Marcus Ngantcha
Eli Lilly and Company, Indianapolis, Indiana, USA

Blessing Ibe
Eli Lilly and Company, Indianapolis, Indiana, USA

Russel Burge
Eli Lilly and Company, Indianapolis, Indiana, USA

Andris Kronbergs
Eli Lilly and Company, Indianapolis, Indiana, USA

Norman Madsen
University of Rochester, Rochester, New York, USA

Keywords

Obesity, Quality of life, psoriatic arthritis, Residual Disease Activity

References

1. Siebert S, et al. Joint Bone Spine. 2025;92:105904.

2. di Minno MN, et al. Arthritis Care Res (Hoboken). 2013;65:141-147.

3. Eder L, et al. Ann Rheum Dis. 2015;74:813-817.

4. Vallejo-Yagüe E, et al. BMJ Open. 2022;12:e061474.

5. Mease PJ, et al. Ann Rheum Dis. 2017;76:79-87.

6. Nash P, et al. Lancet. 2017;389:2317-2327.

7. Mease PJ, et al. Ann Rheum Dis. 2020;79:123-131.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/2hrz2v73

Article Details

How to Cite
1.
Obesity Is Associated With Residual Disease Activity and Lower Quality of Life in Patients Who Achieve Clinical Response to Psoriatic Arthritis Treatment: Post Hoc Analysis From the SPIRIT Studies. J of Skin. 2025;9(6):s694. doi:10.25251/2hrz2v73
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Psoriatic Arthritis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>